Two Phase 3 studies have demonstrated that patients can safely switch between adalimumab, a well-known biologic therapy, and ...

Biocon Biologics presents dermatology data at EADV 2024 Congress, showcasing interchangeability and biosimilarity of ...

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced new dermatology data ...

Kiran Mazumdar-Shaw has reaffirmed that Biocon is not for sale, despite market rumours. The company is focusing on reducing ...

The global psoriatic arthritis (PsA) treatment market is poised for remarkable expansion, with an anticipated valuation of ...

Shares of Regeneron Pharmaceuticals, Inc. REGN were down 4.63% after an unfavorable ruling in its lawsuit against Amgen AMGN ...

Here’s a quick look at stocks likely to be in focus in today's trade. Vedanta: Metals conglomerate Vedanta Ltd will review ...

Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its ...

Biocon Biologics presents new dermatology data from two clinical studies at EADV Congress 2024: Our Bureau, Bengaluru Wednesday, September 25, 2024, 13:40 Hrs [IST] Biocon Biologi ...

Bangalore: Biocon has announced that the U.S. Food and Drug Administration (US FDA) has concluded a surveillance inspection ...

Under the terms of this agreement, Biocon will develop and manufacture the products, and Tabuk Pharmaceuticals will hold the ...

Piramal Pharma aims to double its revenue to $2 billion by FY30, while tripling its Ebitda, said company Chairperson Nandini ...